Evidence map›Paper›PMID 25314136›Full record

ArticlePloS one2014

Resveratrol increases nitric oxide production in the rat thick ascending limb via Ca2+/calmodulin.

Agustin Gonzalez-Vicente, Pablo D Cabral, Jeffrey L Garvin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Agustin Gonzalez-VicenteDepartment of Physiology and Biophysics, Case Western Reserve University, School of Medicine, Cleveland, Ohio, United States of America; Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Pablo D CabralDepartment of Physiology and Biophysics, Case Western Reserve University, School of Medicine, Cleveland, Ohio, United States of America; Universidad de Buenos Aires, Facultad de Medicina, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Jeffrey L GarvinDepartment of Physiology and Biophysics, Case Western Reserve University, School of Medicine, Cleveland, Ohio, United States of America; Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, United States of America.
Case Western Reserve University · USHenry Ford Hospital · USUniversity of Buenos Aires · AR

Funding

TUMOR NECROSIS FACTOR, EICOSANOIDS AND LUNG INJURYF32HL007985 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI KRUSE-ELLIOTT, KRIS · 1988 to 1991
–
NHLBI NIH HHS HL 07985
6 · The paper itself

Abstract

The thick ascending limb of the loop of Henle reabsorbs 30% of the NaCl filtered through the glomerulus. Nitric oxide (NO) produced by NO synthase 3 (NOS3) inhibits NaCl absorption by this segment. Resveratrol, a polyphenol, has beneficial cardiovascular and renal effects, many of which are mediated by NO. Resveratrol increases intracellular Ca2+ (Cai) and AMP kinase (AMPK) and NAD-dependent deacetylase sirtuin1 (SIRT1) activities, all of which could activate NO production. We hypothesized that resveratrol stimulates NO production by thick ascending limbs via a Ca2+/calmodulin-dependent mechanism. To test this, the effect of resveratrol on NO bioavailability was measured in thick ascending limb suspensions. Cai was measured in single perfused thick ascending limbs. SIRT1 activity and expression were measured in thick ascending limb lysates. Resveratrol (100 µM) increased NO bioavailability in thick ascending limb suspensions by 1.3±0.2 AFU/mg/min (p<0.03). The NOS inhibitor L-NAME blunted resveratrol-stimulated NO bioavailability by 96±11% (p<0.03). The superoxide scavenger tempol had no effect. Resveratrol elevated Cai from 48±7 to 135±24 nM (p<0.01) in single tubules. In Ca2+-free media, the resveratrol-induced increase in NO was blunted by 60±20% (p<0.05) and the rise in Cai reduced by 80%. Calmodulin inhibition prevented the resveratrol-induced increase in NO (p<0.002). AMPK inhibition had no effect. Resveratrol did not increase SIRT1 activity. We conclude that resveratrol increases NO production in thick ascending limbs via a Ca2+/calmodulin dependent mechanism, and SIRT1 and AMPK do not participate. Resveratrol-stimulated NO production in thick ascending limbs may account for part of its beneficial effects.

Indexed as

AMP-Activated Protein KinasesAnimalsCalciumCalmodulinGene ExpressionLoop of HenleNitric OxideProtein Kinase InhibitorsRatsResveratrolSignal TransductionSirtuin 1StilbenesSulfonamidesAMP-Activated Protein KinasesCalciumCalmodulinNitric OxideProtein Kinase InhibitorsResveratrolSirt1 protein, ratSirtuin 1StilbenesSulfonamidesW 7

Identifiers

PMID25314136
PMCPMC4196991
OpenAlexW2023719514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.